Logo image of NYKD.OL

NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Fundamental Analysis

Europe - OSL:NYKD - NO0010714785 - Common Stock

1.703 NOK
-0.05 (-2.69%)
Last: 10/8/2025, 11:03:45 AM
Fundamental Rating

3

NYKD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. The financial health of NYKD is average, but there are quite some concerns on its profitability. NYKD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NYKD has reported negative net income.
NYKD had a negative operating cash flow in the past year.
In the past 5 years NYKD reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: NYKD reported negative operating cash flow in multiple years.
NYKD.OL Yearly Net Income VS EBIT VS OCF VS FCFNYKD.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

The Return On Assets of NYKD (-17.27%) is better than 63.01% of its industry peers.
NYKD's Return On Equity of -18.90% is fine compared to the rest of the industry. NYKD outperforms 68.49% of its industry peers.
Industry RankSector Rank
ROA -17.27%
ROE -18.9%
ROIC N/A
ROA(3y)-20.49%
ROA(5y)0.02%
ROE(3y)-25.42%
ROE(5y)0.53%
ROIC(3y)N/A
ROIC(5y)N/A
NYKD.OL Yearly ROA, ROE, ROICNYKD.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

NYKD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NYKD.OL Yearly Profit, Operating, Gross MarginsNYKD.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

6

2. Health

2.1 Basic Checks

NYKD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NYKD has about the same amount of shares outstanding.
Compared to 5 years ago, NYKD has more shares outstanding
Compared to 1 year ago, NYKD has an improved debt to assets ratio.
NYKD.OL Yearly Shares OutstandingNYKD.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
NYKD.OL Yearly Total Debt VS Total AssetsNYKD.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 2.78 indicates that NYKD is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of NYKD (2.78) is better than 72.60% of its industry peers.
NYKD has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of NYKD (0.02) is better than 75.34% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 2.78
ROIC/WACCN/A
WACC8.47%
NYKD.OL Yearly LT Debt VS Equity VS FCFNYKD.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

NYKD has a Current Ratio of 16.92. This indicates that NYKD is financially healthy and has no problem in meeting its short term obligations.
NYKD has a better Current ratio (16.92) than 95.89% of its industry peers.
A Quick Ratio of 16.92 indicates that NYKD has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 16.92, NYKD belongs to the best of the industry, outperforming 97.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.92
Quick Ratio 16.92
NYKD.OL Yearly Current Assets VS Current LiabilitesNYKD.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.47% over the past year.
Looking at the last year, NYKD shows a very negative growth in Revenue. The Revenue has decreased by -25.95% in the last year.
NYKD shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -36.54% yearly.
EPS 1Y (TTM)90.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.2%
Revenue 1Y (TTM)-25.95%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to decrease by -66.63% on average over the next years. This is quite bad
Based on estimates for the next years, NYKD will show a very strong growth in Revenue. The Revenue will grow by 184.95% on average per year.
EPS Next Y53.23%
EPS Next 2Y20.3%
EPS Next 3Y14.21%
EPS Next 5Y-66.63%
Revenue Next Year-86.43%
Revenue Next 2Y-41.42%
Revenue Next 3Y52.25%
Revenue Next 5Y184.95%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NYKD.OL Yearly Revenue VS EstimatesNYKD.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
NYKD.OL Yearly EPS VS EstimatesNYKD.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NYKD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NYKD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYKD.OL Price Earnings VS Forward Price EarningsNYKD.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYKD.OL Per share dataNYKD.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as NYKD's earnings are expected to grow with 14.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.3%
EPS Next 3Y14.21%

More info and screens

6

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 59.74%, NYKD is a good candidate for dividend investing.
NYKD's Dividend Yield is rather good when compared to the industry average which is at 13.34. NYKD pays more dividend than 100.00% of the companies in the same industry.
NYKD's Dividend Yield is rather good when compared to the S&P500 average which is at 2.44.
Industry RankSector Rank
Dividend Yield 59.74%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DPN/A
EPS Next 2Y20.3%
EPS Next 3Y14.21%
NYKD.OL Yearly Income VS Free CF VS DividendNYKD.OL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

More info and screens

NYKODE THERAPEUTICS ASA

OSL:NYKD (10/8/2025, 11:03:45 AM)

1.703

-0.05 (-2.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-20 2025-08-20
Earnings (Next)11-26 2025-11-26
Inst Owners15.07%
Inst Owner ChangeN/A
Ins Owners0.96%
Ins Owner ChangeN/A
Market Cap556.11M
Analysts42.22
Price Target5.25 (208.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 59.74%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.98%
PT rev (3m)0.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)21.43%
EPS NY rev (3m)43.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-88.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.12
P/FCF N/A
P/OCF N/A
P/B 0.42
P/tB 0.42
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-1.45
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS0.24
BVpS4.08
TBVpS4.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.27%
ROE -18.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.49%
ROA(5y)0.02%
ROE(3y)-25.42%
ROE(5y)0.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.05%
Cap/Sales 1.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.92
Quick Ratio 16.92
Altman-Z 2.78
F-Score4
WACC8.47%
ROIC/WACCN/A
Cap/Depr(3y)80.08%
Cap/Depr(5y)78.32%
Cap/Sales(3y)17.63%
Cap/Sales(5y)11.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.2%
EPS Next Y53.23%
EPS Next 2Y20.3%
EPS Next 3Y14.21%
EPS Next 5Y-66.63%
Revenue 1Y (TTM)-25.95%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-86.43%
Revenue Next 2Y-41.42%
Revenue Next 3Y52.25%
Revenue Next 5Y184.95%
EBIT growth 1Y31.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.24%
EBIT Next 3Y17.05%
EBIT Next 5Y-60.17%
FCF growth 1Y10.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.72%
OCF growth 3YN/A
OCF growth 5YN/A